NCT01467375View on ClinicalTrials.gov

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

January 8, 2001

Primary Completion Date

October 22, 2004

Study Completion Date

October 22, 2004

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner

Trial Locations (12)

2292

Novo Nordisk Investigational Site, Broadmeadow

2540

Novo Nordisk Investigational Site, Nowra

2766

Novo Nordisk Investigational Site, Rooty Hill

3052

Novo Nordisk Investigational Site, Parkville

3134

Novo Nordisk Investigational Site, Ringwood

4066

Novo Nordisk Investigational Site, Auchenflower

5035

Novo Nordisk Investigational Site, Ashford

7250

Novo Nordisk Investigational Site, Launceston

J8Y 1W1

Novo Nordisk Investigational Site, Hull

N6A 4L6

Novo Nordisk Investigational Site, London

G1V 4G2

Novo Nordisk Investigational Site, Québec

S7N 0W8

Novo Nordisk Investigational Site, Saskatoon

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY